Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis

References

1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med2000;343:1586–93.10.1056/NEJM200011303432201Search in Google Scholar PubMed

2. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med2000;343:1594–602.10.1056/NEJM200011303432202Search in Google Scholar PubMed

3. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum2002;46:283–5.10.1002/art.10092Search in Google Scholar PubMed

4. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum2002;46:347–56.10.1002/art.10083Search in Google Scholar PubMed

5. Nienhuis RL, Mandema EA. A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis1964;23:302–5.10.1136/ard.23.4.302Search in Google Scholar PubMed PubMed Central

6. Youinou P, Le Goff P, Maran R. Perinuclear factor (profilaggrin) autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier Science BV, 1996:618–23.Search in Google Scholar

7. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Antikeratin antibodies in rheumatoid arthritis. Br Med J1979;2:97–9.10.1136/bmj.2.6182.97Search in Google Scholar PubMed PubMed Central

8. Serre G, Vincent C. Filaggrin (keratin) autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier Science BV, 1996:271–6.Search in Google Scholar

9. Miossec P, Youinou P, Le Goff P, Moineau MP. Clinical relevance of antikeratin antibodies in rheumatoid arthritis. Clin Rheumatol1982;1:185–9.10.1007/BF02042772Search in Google Scholar PubMed

10. Simon M, Girbal E, Sebbag M, Gomès-Daudrix V, Vincent C, Salama G, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called “antikeratin antibodies”, autoantibodies specific for rheumatoid arthritis. J Clin Invest1993;92:1387–93.10.1172/JCI116713Search in Google Scholar PubMed PubMed Central

11. Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest1995;95:2672–9.10.1172/JCI117969Search in Google Scholar PubMed PubMed Central

12. Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis1991;50:611–8.10.1136/ard.50.9.611Search in Google Scholar PubMed PubMed Central

13. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest1998;101:273–81.10.1172/JCI1316Search in Google Scholar

14. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol1999;162:585–94.10.4049/jimmunol.162.1.585Search in Google Scholar

15. Asaga H, Yamada M, Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun1998;243:641–6.10.1006/bbrc.1998.8148Search in Google Scholar

16. van Venrooij WJ, Pruijn GJ. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res2000;2:249–51.10.1186/ar95Search in Google Scholar

17. López-Hoyos M, Marquina R, Tamayo E, Gonzales-Rojas J, Izui S, Merino R, et al. Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice. Arthritis Rheum2003;48:2353–61.10.1002/art.11107Search in Google Scholar

18. Masson-Bessiere C, Sebbag M, Durieux JJ, Norgueira L, Vincent C, Girbal-Neuhauser E, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol2000;119:544–52.10.1046/j.1365-2249.2000.01171.xSearch in Google Scholar

19. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium. Arthritis Rheum2001;44:2255–62.10.1002/1529-0131(200110)44:10<2255::AID-ART388>3.0.CO;2-#Search in Google Scholar

20. Smeets TJ, Vossenaar ER, Kraan MC, van Mansum WA, Raats JM, van Venrooij WJ, et al. Expression of citrullin-containing antigens in RA synovium. Arthritis Res2001;3(Suppl A):P004.10.1186/ar173Search in Google Scholar

21. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum2001;44:41–7.10.1002/1529-0131(200101)44:1<41::AID-ANR6>3.0.CO;2-0Search in Google Scholar

22. Ishida-Yamamoto A, Hashimoto Y, Manabe M, O'Guin WM, Dale BA, Iizuka H. Distinctive expression of filaggrin and trichohyalin during various pathways of epithelial differentiation. Br J Dermatol1997;137:9–16.10.1046/j.1365-2133.1997.17611855.xSearch in Google Scholar

23. Vossenaar ER, van Venrooij WJ, Pruijn GJ. Anti-CCP antibodies in (early) rheumatoid arthritis. In: Conrad K, Fritzler M, Meurer M, Sack U, Shoenfeld Y, editors. From proteonomics to molecular epidemiology: relevance of autoantibodies. Lengerich: Pabst Science Publishers, 2002:454–62.Search in Google Scholar

24. Vossenaar ER, Nijenhuis S, Helsen MM, van der Heijden A, Senshu T, van der Berg WB, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum2003;48:2489–500.10.1002/art.11229Search in Google Scholar

25. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol2001;166:4177–84.10.4049/jimmunol.166.6.4177Search in Google Scholar PubMed

26. Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther2005;7:R1421–9.10.1186/ar1845Search in Google Scholar PubMed PubMed Central

27. Després N, Boire G, Lopez-Longo FJ, Ménard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol1994;21:1027–33.Search in Google Scholar

28. Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, Benali K, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol1999;26:7–13.Search in Google Scholar

29. Hueber W, Hassfeld W, Smolen JS, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford)1999;38:155–9.10.1093/rheumatology/38.2.155Search in Google Scholar PubMed

30. Xu S, Tang F, Shi L, Gan X, Shi Y, Cheng L, et al. AntiSa antibody in Chinese rheumatoid arthritis. Chin Med J1998;111:204–7.Search in Google Scholar

31. Ménard HA, Lapointe E, Rochdi MD, Zhou ZJ. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res2000;2:429–32.10.1186/ar122Search in Google Scholar PubMed PubMed Central

32. Vossenaar ER, Després N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther2004;6:R142–50.10.1186/ar1149Search in Google Scholar PubMed PubMed Central

33. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis2004;63:373–81.10.1136/ard.2003.012211Search in Google Scholar PubMed PubMed Central

34. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol2003;5:59–63.10.1038/ncb898Search in Google Scholar PubMed

35. Vincent C, Simon M, Sebbag M, Girbal-Neuhauser E, Durieux JJ, Cantagrel A, et al. Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. J Rheumatol1998;25:838–46.Search in Google Scholar

36. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum2002;46:1185–95.10.1002/art.10229Search in Google Scholar PubMed

37. Palosuo T, Lukka M, Alenius H, Kalkkinen N, Aho K, Kurki P, et al. Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol1998;115:294–302.10.1159/000069460Search in Google Scholar PubMed

38. Nogueira L, Sebbag M, Vincent C, Arnaud M, Fournié B, Cantagrel A, et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis2001;60:882–7.Search in Google Scholar

39. Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol2004;135:173–80.10.1111/j.1365-2249.2004.02341.xSearch in Google Scholar PubMed PubMed Central

40. Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourner O, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay. A highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum2002;46:2051–8.10.1002/art.10436Search in Google Scholar

41. Nogueira L, Foussadier A, Vincent C. VIDAS-EDRA fully automated testing of autoantibodies to citrullinated proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther2004;6:S5.Search in Google Scholar

42. Bizzaro N, Pasini P, Mazzanti G, Villalta D, Tonutti E, Tozzoli R. Combined use of the anti-filaggrin and anti-cyclic citrullinated peptide antibody assays for the diagnosis of rheumatoid arthritis. Autoimmunity Rev2002;1:65.Search in Google Scholar

43. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum2000;43:155–63.10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3Search in Google Scholar

44. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem2001;47:1089–93.10.1093/clinchem/47.6.1089Search in Google Scholar

45. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology2002;41:809–14.10.1093/rheumatology/41.7.809Search in Google Scholar

46. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford)2003;42:677–80.10.1093/rheumatology/keg184Search in Google Scholar

47. Bizzaro N, van Venrooij WJ. [Anti-citrulline antibodies: higher sensitivity of second generation immunoassays (CCP2)]. Riv Med Lab2002;2:255. Italian.Search in Google Scholar

48. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med2002;60:383–8.Search in Google Scholar

49. Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol2003;32:197–204.10.1080/03009740310003677Search in Google Scholar

50. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis2003;62:870–4.10.1136/ard.62.9.870Search in Google Scholar

51. Pinheiro GC, Scheinberg MA, Aparecida DS, Maciel S. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med2003;139:234–5.10.7326/0003-4819-139-3-200308050-00021Search in Google Scholar

52. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab2002;21:34–6.Search in Google Scholar

53. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first- and second anti-cyclic citrullinated peptides autoantibody (CCP1 and CCP2) tests for rheumatoid arthritis. Ann Rheum Dis2005;64:1510–2.10.1136/ard.2004.035089Search in Google Scholar

54. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann NY Acad Sci2005;1050:295–303.10.1196/annals.1313.031Search in Google Scholar

55. Fernández-Suárez A, Reneses S, Wichmann I, Criado R, Núñez A. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis. Clin Chem Lab Med2005;43:1234–9.10.1515/CCLM.2005.214Search in Google Scholar

56. Egerer K, Bang H, Lãthke K, Gauliard A, Feist E, Rudolph PE, et al. A new powerful marker for the diagnosis and prognosis of rheumatoid arthritis: anti-CVM (anti-citrullinated vimentin mutated) antibodies. Arthritis Rheum2005;52:S118.Search in Google Scholar

57. Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis2004;63:415–9.10.1136/ard.2003.008623Search in Google Scholar

58. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis2004;63:1587–93.10.1136/ard.2003.017574Search in Google Scholar

59. Sauerland U, Becker H, Seidel M, Schotte H, Willeke P, Schorat A, et al. Clinical utility of the anti-CCP assay. Experiences with 700 patients. Ann NY Acad Sci2005;1050:314–8.10.1196/annals.1313.033Search in Google Scholar

60. Palosuo T, Tilvis R, Strandberg T, Aho K. Filaggrin related antibodies among the aged. Ann Rheum Dis2003;62:261–3.10.1136/ard.62.3.261Search in Google Scholar

61. Leone N, Pellicano R, Ariata Maiocco I, Modena V, Marietti G, Rizzetto M, et al. Mixed cryoglobulinaemia and chronic hepatitis C virus infection: the rheumatic manifestations. J Med Virol2002;66:200–3.10.1002/jmv.2130Search in Google Scholar

62. Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin North Am2003;29:111–22.10.1016/S0889-857X(02)00097-2Search in Google Scholar

63. Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum2004;50:2305–8.10.1002/art.20355Search in Google Scholar PubMed

64. Bombardieri M, Alessandri C, Labbadia G, Iannuccelli C, Carlucci F, Riccieri V, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther2004;6:R137–41.10.1186/ar1041Search in Google Scholar PubMed PubMed Central

65. Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis2001;60:67–8.10.1136/ard.60.1.67Search in Google Scholar PubMed PubMed Central

66. Gottenberg JE, Mignot S, Nicaise-Rolland P, Cohen-Solal J, Aucouturier F, Goetz J, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis2005;64:114–7.10.1136/ard.2003.019794Search in Google Scholar PubMed PubMed Central

67. van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol2033;30:825–8.Search in Google Scholar

68. Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis2002;61:608–11.10.1136/ard.61.7.608Search in Google Scholar PubMed PubMed Central

69. Prahalad S, Glass DN. Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis? Arthritis Res2003;4(Suppl 3):303–10.10.1186/ar594Search in Google Scholar

70. Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol2004;31:1829–33.Search in Google Scholar

71. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum1987;30:1205–13.10.1002/art.1780301102Search in Google Scholar PubMed

72. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum2004;50:2113–21.10.1002/art.20316Search in Google Scholar PubMed

73. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 Shared Epitope for antibodies to citrullinated proteins. Arthritis Rheum2005;52:3433–8.10.1002/art.21385Search in Google Scholar PubMed

74. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther2005;7:R949–58.10.1186/ar1767Search in Google Scholar PubMed PubMed Central

75. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum2005;52:3058–62.10.1002/art.21302Search in Google Scholar PubMed

76. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum2003;48:2741–9.10.1002/art.11223Search in Google Scholar PubMed

77. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum2004;50:380–6.10.1002/art.20018Search in Google Scholar PubMed

78. Mandl LA, Costenbader K, Chibnik L, Schur P, Karlson EW. Anti-cyclic citrullinated peptide (anti-CCP) antibodies are strongly associated with risk of rheumatoid arthritis after adjusting for hormonal and behavioral factors. Arthritis Rheum2005;52:S732.Search in Google Scholar

79. Deane KD, Majka DS, Parrish LA, Baron AE, Gilliland WR, Walker CW, et al. RA-related antibodies appear earlier in the pre-clinical period in subjects with an older age at disease onset. Arthritis Rheum2005;52:S154.Search in Google Scholar

80. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol2003;30:1691–5.Search in Google Scholar

81. van Gaalen FA, Linn-Rasker S, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum2004;50:709–15.10.1002/art.20044Search in Google Scholar

82. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund G, van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with the future onset of rheumatoid arthritis. Arthritis Res Ther2004;6:R303–8.10.1186/ar1187Search in Google Scholar

83. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum2002;46:357–65.10.1002/art.10117Search in Google Scholar

84. Muñoz-Fernández S, Alvarez-Doforno R, González-Tarrio JM, Balsa A, Richi P, Fontan G, et al. Antiperinuclear factor as a prognostic marker in rheumatoid arthritis. J Rheumatol1999;26:2572–7.Search in Google Scholar

85. Kroot E, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of the anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum2000;43:1831–5.10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6Search in Google Scholar

86. van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol1999;17:689–97.Search in Google Scholar

87. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis2003;62:120–6.10.1136/ard.62.2.120Search in Google Scholar

88. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chales G, Le Henaff C, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol2003;30:2535–9.Search in Google Scholar

89. Vencovský J, Machácek S, Šedová L, Kafková J, Gatterová J, Pesaková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis2003;62:427–30.10.1136/ard.62.5.427Search in Google Scholar

90. Jansen AL, van der Horst-Bruinsma IE, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol2002;29:2074–6.Search in Google Scholar

91. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project). Ann Rheum Dis2004;63:1085–9.10.1136/ard.2003.016808Search in Google Scholar

92. Chan MT, Owen P, Dunphy J, Carmichael C, Turner C, McHugh NJ. Anti-cyclic citrullinated peptide antibodies are associated with erosive arthritis in SLE. Arthritis Rheum2005;52:S611.Search in Google Scholar

93. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early RA in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis2004;63:1090–5.10.1136/ard.2003.014233Search in Google Scholar

94. Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who receiv-ed different treatment strategies. Am J Med2001;111:446–51.10.1016/S0002-9343(01)00872-5Search in Google Scholar

95. Nell V, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology2004;43:906–14.10.1093/rheumatology/keh199Search in Google Scholar

96. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum2004;50:1051–65.10.1002/art.20159Search in Google Scholar PubMed

97. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther2004;6:R264–72.10.1186/ar1173Search in Google Scholar PubMed PubMed Central

98. De Rycke L, Verhelst X, Kruithof E, van den Bosch F, Hoffman IE, Veys EM, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis2005;64:299–302.10.1136/ard.2004.023523Search in Google Scholar PubMed PubMed Central

99. Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int2005;26:58–62.10.1007/s00296-004-0571-9Search in Google Scholar PubMed

100. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following ant-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis2004;63:1218–21.10.1136/ard.2003.014647Search in Google Scholar PubMed PubMed Central

101. Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum2004;50:3776–82.10.1002/art.20659Search in Google Scholar PubMed

102. Sivhonen S, Korpela M, Mustila A, Mustonen J. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol2005;32:2089–94.Search in Google Scholar

103. Kamoun M. Diagnostic performance and predictive value of anti-citrullinated peptide antibodies for diagnosis of rheumatoid arthritis: toward more accurate detection? Clin Chem2005;51:12–3.10.1373/clinchem.2004.043018Search in Google Scholar PubMed